Latest treatment news and information for patient advocates and people working in hepatitis in Europe. Find out more about infohep >

Dr Kosh Agarwal discusses results of the REEF-2 study at the International LIver Congress. Photo © Steve Forrest & Andrew McConnell / EASL.Dr Kosh Agarwal discusses results of the REEF-2 study at the International LIver Congress. Photo © Steve Forrest & Andrew McConnell / EASL.

News from the International Liver Congress 2022

Experimental hepatitis B combination suppresses key marker but fails to achieve functional cure.

New & experimental hepatitis B treatments

New & experimental hepatitis B treatments

Bepirovirsen suppresses hepatitis B surface antigen, moves forward to larger functional cure studies.

Professor Heiner Wedemeyer of Hannover Medical School speaking at an International Liver Congress press conference. Photo © Steve Forrest & Andrew McConnell / EASL.Professor Heiner Wedemeyer of Hannover Medical School speaking at an International Liver Congress press conference. Photo © Steve Forrest & Andrew McConnell / EASL.

Hepatitis D

Bulevirtide leads to sustained improvement for people with hepatitis D.

Factsheets

Factsheets

Read our updated hepatitis C treatment factsheets on infohep.

Hepatitis bulletin

Hepatitis bulletin

Sign up for our monthly hepatitis bulletin.

infohep news

Latest library resources

Looking for country specific news and resources?

Looking for country specific news and resources?

Visit our country information pages >

Keep up to date with the latest hepatitis news

Keep up to date with the latest hepatitis news

Sign up for our free monthly email bulletin >